GlaxoSmithKline Pharmaceuticals Ltd. reported a 12% year-on-year increase in net profit for the quarter ended June 2025, buoyed by robust consumer healthcare sales and strategic cost containment. The company’s performance was supported by sustained demand across key therapeutic segments, a disciplined approach to operational expenses, and growth in its flagship brands. Revenue also saw a modest uptick, reflecting broader market stability in the pharmaceutical sector.